Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Organon - Caught on Camera

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This…

The Economic Times

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore.…

The Economic Times

SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

When the world's an oyster for Sun (Pharma)

Indian companies are increasingly making bold acquisitions abroad. Sun Pharma's deal signals a new era of deliberate empire-building. This shift from tentative deals to strategic bets is crucial for global relevance. Successful acquisitions require clear intent, respect for acquired assets, integration discipline, financial courage, and a long-term mindset.

The Economic Times

S&P 500, Nasdaq Nab Best Weeks Since November: Stock Market Today

Strong gains in mega-cap tech stocks buoyed the Nasdaq on Friday, but the Dow and S&P 500 weren't so resilient.

Kiplinger

Organon Cuts 2025 Sales Outlook Despite Earnings Beat

Organon (NYSE:OGN) reported third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion, beating the Wall Street estimate of $1.56 billion.

Benzinga

5 Stocks to Buy for a Harris Presidency

The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

If companies don't train Gen Zers, they'll train themselves

Gen Z is having a hard time getting entry-level jobs, plus companies are hiring fewer interns.

Fortune

3 Cheap Small-Cap Stocks to Scoop Up on the Market Pullback

With small-cap stocks grabbing investors' attention lately, here are three discounted names with solid fundamentals to grab now, while the retracement provides a prime entry point.

Barchart

3 Healthcare Stocks With The Highest Yields As of June 2024

Looking for yield? Here's 3 healthcare stocks with the highest yields today.

Barchart

Warning over asthma drug after 500 neuropsychiatric reactions reported in young children

UK medicines regulator says information accompanying montelukast will alert users to risk of mood and behaviour changes

The Guardian - UK

Safety fears over asthma drug after young children suffer severe side effects

Campaigners call for more warnings on montelukast, after reports of night terrors, depression and other mental health events

The Guardian - UK

Want long-term contraception? There are more effective options than the pill. But they can be hard to find

Australians’ access to a range of contraceptive options depends on where they live and how wealthy they are. A recent parliamentary inquiry recommends ways to end this “postcode lottery” for people who want to use long-acting reversible contraception.

The Conversation

A simple device could prevent thousands of maternal deaths. Why did it take so long to get to market?

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Bangkok Post

Organon prioritises cross-sectoral collaboration to drive 'Smart Families' progress

Unintended pregnancy remains a significant global health issue. A recent UNFPA report suggesting nearly half of all pregnancies, totaling 121 million each year worldwide, are unintended and more than 160 million women have limited access to contraceptives.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022

Upgrades

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

Benzinga

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Organon & Co (NYSE: OGN)

Liverpool Echo

Woman covered in burning red rash after taking contraceptive pill

Ella Holley thought the painful red rash was caused by her unhealthy lifestyle of alcohol and late nights

Daily Mirror

Student who thought spotty rash was from partying is told it's a side effect of the pill

Ella Holley initially thought the angry red blotches had been caused by the unhealthy student lifestyle, but is now trying to raise awareness around the potential side effects of taking the contraceptive pill

Benzinga

Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B

Organon & Co's (NYSE: OGN)

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Kennedy News and Media

676 stories

Jefferies

657 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.